Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

AIM: Apixaban is an oral, direct, factor-Xa inhibitor approved for thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery and for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. This open label, parallel group study in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Upreti, Vijay V, Wang, Jessie, Barrett, Yu Chen, Byon, Wonkyung, Boyd, Rebecca A, Pursley, Janice, LaCreta, Frank P, Frost, Charles E
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Science Inc 2013
Konular:
Pharmacokinetic Dynamic Relationships
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3845314/
https://ncbi.nlm.nih.gov/pubmed/23488672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12114
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller